PLEKHA4

Summary

PLEKHA4 (pleckstrin homology domain containing A4, HGNC:14339) is a protein-coding gene on chromosome 19q13.33, encoding Pleckstrin homology domain-containing family A member 4 (Q9H4M7). Binds specifically to phosphatidylinositol 3-phosphate (PtdIns3P), but not to other phosphoinositides.

This gene encodes a pleckstrin homology (PH) domain-containing protein. The PH domain is found near the N-terminus and contains a putative phosphatidylinositol 3, 4, 5-triphosphate-binding motif (PPBM). Elevated expression of this gene has been observed in some melanomas. Alternate splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 57664 — RefSeq curated summary.

At a glance

• GWAS associations: 20
• Clinical variants (ClinVar): 190 total
• MANE Select transcript: NM_020904

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14339
Approved symbol	PLEKHA4
Name	pleckstrin homology domain containing A4
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	PEPP1
Ensembl gene	ENSG00000105559
Ensembl biotype	protein_coding
OMIM	607769
Entrez	57664

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 23 protein_coding, 6 protein_coding_CDS_not_defined, 4 retained_intron, 3 nonsense_mediated_decay

ENST00000263265, ENST00000355496, ENST00000593696, ENST00000594100, ENST00000594195, ENST00000595867, ENST00000596713, ENST00000596982, ENST00000597129, ENST00000597406, ENST00000601146, ENST00000706736, ENST00000706737, ENST00000706738, ENST00000706739, ENST00000706740, ENST00000882966, ENST00000882967, ENST00000882968, ENST00000882969, ENST00000882970, ENST00000882971, ENST00000882972, ENST00000882973, ENST00000882974, ENST00000882975, ENST00000882976, ENST00000882977, ENST00000882978, ENST00000882979, ENST00000882980, ENST00000882981, ENST00000956195, ENST00000956196, ENST00000956197, ENST00000956198

RefSeq mRNA: 2 — MANE Select: NM_020904 NM_001161354, NM_020904

CCDS: CCDS12737, CCDS54291

Canonical transcript exons

ENST00000263265 — 20 exons

Exon	Start	End
ENSE00000718336	48865503	48865610
ENSE00000853366	48861620	48861692
ENSE00001130298	48858860	48859139
ENSE00003081233	48868083	48868617
ENSE00003109576	48867537	48867626
ENSE00003612362	48859469	48859684
ENSE00003620657	48837097	48837551
ENSE00003654297	48860350	48860459
ENSE00003692398	48861401	48861501
ENSE00003996638	48847900	48848040
ENSE00003996639	48839205	48839263
ENSE00003996640	48852228	48852326
ENSE00003996641	48857422	48857496
ENSE00003996643	48845370	48845446
ENSE00003996644	48845517	48845616
ENSE00003996645	48841149	48841310
ENSE00003996646	48838017	48838129
ENSE00003996800	48853682	48853831
ENSE00003996808	48854007	48854087
ENSE00003996817	48854217	48854264

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 99.29.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5427 / max 270.8328, expressed in 800 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181943	0.8483	348
181942	0.7365	162
208889	0.5477	224
181941	0.3079	136
181940	0.1024	39

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	99.29	gold quality
tibial nerve	UBERON:0001323	99.24	gold quality
trigeminal ganglion	UBERON:0001675	95.35	gold quality
descending thoracic aorta	UBERON:0002345	95.06	gold quality
dorsal root ganglion	UBERON:0000044	93.52	gold quality
apex of heart	UBERON:0002098	93.26	gold quality
right ovary	UBERON:0002118	92.98	gold quality
thoracic aorta	UBERON:0001515	92.86	gold quality
mucosa of stomach	UBERON:0001199	92.73	gold quality
ascending aorta	UBERON:0001496	92.68	gold quality
left coronary artery	UBERON:0001626	92.67	gold quality
left ovary	UBERON:0002119	92.23	gold quality
tendon of biceps brachii	UBERON:0008188	92.12	gold quality
coronary artery	UBERON:0001621	91.39	gold quality
adenohypophysis	UBERON:0002196	91.13	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.53	gold quality
right coronary artery	UBERON:0001625	90.49	gold quality
left uterine tube	UBERON:0001303	90.44	gold quality
right atrium auricular region	UBERON:0006631	90.16	gold quality
lower esophagus	UBERON:0013473	90.11	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.11	gold quality
aorta	UBERON:0000947	89.93	gold quality
muscle layer of sigmoid colon	UBERON:0035805	89.86	gold quality
body of uterus	UBERON:0009853	89.74	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	89.50	gold quality
right lobe of thyroid gland	UBERON:0001119	89.31	gold quality
right lobe of liver	UBERON:0001114	88.83	gold quality
left lobe of thyroid gland	UBERON:0001120	88.54	gold quality
cardiac atrium	UBERON:0002081	88.27	gold quality
omental fat pad	UBERON:0010414	88.06	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	1160.76
E-MTAB-7052	yes	172.38
E-MTAB-8142	yes	15.18
E-ANND-3	yes	10.96

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting PLEKHA4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-520G-3P	98.91	67.38	1914
HSA-MIR-520H	98.91	67.38	1914
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-615-5P	98.10	63.76	591
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-320E	97.49	65.96	865
HSA-MIR-3187-3P	97.38	65.80	904
HSA-MIR-4313	97.18	63.15	420
HSA-MIR-181D-3P	96.23	63.96	81
HSA-MIR-7976	95.75	65.67	1186
HSA-MIR-1228-5P	93.60	63.91	91
HSA-MIR-6795-3P	91.86	63.00	218

Literature-anchored findings (GeneRIF, showing 5)

• PLEKHA4/kramer Attenuates Dishevelled Ubiquitination to Modulate Wnt and Planar Cell Polarity Signaling. (PMID:31091453)
• PLEKHA4 Promotes Wnt/beta-Catenin Signaling-Mediated G1-S Transition and Proliferation in Melanoma. (PMID:33574086)
• PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma. (PMID:36714030)
• PLEKHA4 is Associated with Tumour Microenvironment, Stemness, Proliferation and Poor Prognosis of Gliomas. (PMID:37735118)
• PLEKHA4 promotes glioblastoma progression through apoptosis inhibition, tumor cell migration, and macrophage infiltration. (PMID:37980830)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-234p6.5	ENSDARG00000071460
mus_musculus	Plekha4	ENSMUSG00000040428
rattus_norvegicus	Plekha4	ENSRNOG00000020942

Paralogs (3): PLEKHA5 (ENSG00000052126), PLEKHA6 (ENSG00000143850), PLEKHA7 (ENSG00000166689)

Protein

Protein identifiers

Pleckstrin homology domain-containing family A member 4 — Q9H4M7 (reviewed: Q9H4M7)

Alternative names: Phosphoinositol 3-phosphate-binding protein 1

All UniProt accessions (5): Q9H4M7, A0A9L9PXT3, M0QXJ3, M0R0J1, M0R2K5

UniProt curated annotations — full annotation on UniProt →

Function. Binds specifically to phosphatidylinositol 3-phosphate (PtdIns3P), but not to other phosphoinositides.

Subcellular location. Cytoplasm. Membrane.

Tissue specificity. Highly expressed in melanoma. Detected at low levels in heart, skeletal muscle, kidney, liver and small intestine.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H4M7-1	1	yes
Q9H4M7-2	2

RefSeq proteins (2): NP_001154826, NP_065955* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR040392	PKHA4-7_PH	Domain
IPR057971	PKHA4-7_TBCA	Domain

Pfam: PF00169, PF25541

UniProt features (33 total): strand 8, compositionally biased region 7, sequence variant 4, splice variant 3, region of interest 3, modified residue 2, sequence conflict 2, helix 2, chain 1, domain 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
1UPQ	X-RAY DIFFRACTION	1.48
8OIO	X-RAY DIFFRACTION	1.95
1UPR	X-RAY DIFFRACTION	2.27

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H4M7-F1	58.18	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 164, 559

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1660499	Synthesis of PIPs at the plasma membrane

MSigDB gene sets: 107 (showing top): MYOGENIN_Q6, GCANCTGNY_MYOD_Q6, GOBP_NON_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_REGULATION_OF_NON_CANONICAL_WNT_SIGNALING_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_NON_CANONICAL_WNT_SIGNALING_PATHWAY

GO Biological Process (2): positive regulation of canonical Wnt signaling pathway (GO:0090263), positive regulation of Wnt signaling pathway, planar cell polarity pathway (GO:2000096)

GO Molecular Function (7): phosphatidylinositol-4,5-bisphosphate binding (GO:0005546), phosphatidylinositol-3-phosphate binding (GO:0032266), identical protein binding (GO:0042802), phosphatidylinositol-3,4-bisphosphate binding (GO:0043325), phosphatidylinositol-3,5-bisphosphate binding (GO:0080025), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (4): cytoplasm (GO:0005737), plasma membrane (GO:0005886), extrinsic component of cytoplasmic side of plasma membrane (GO:0031234), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
PI Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphatidylinositol phosphate binding	3
phosphatidylinositol bisphosphate binding	3
binding	2
cellular anatomical structure	2
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
Wnt signaling pathway, planar cell polarity pathway	1
positive regulation of non-canonical Wnt signaling pathway	1
regulation of Wnt signaling pathway, planar cell polarity pathway	1
protein binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
cytoplasmic side of plasma membrane	1
extrinsic component of plasma membrane	1

Protein interactions and networks

STRING

6385 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLEKHA4	PLEK	P08567	735
PLEKHA4	PLEK2	Q9NYT0	733
PLEKHA4	KLHL12	Q53G59	696
PLEKHA4	TMEM65	Q6PI78	507
PLEKHA4	M0QYG6	M0QYG6	506
PLEKHA4	PLEKHA3	Q9HB20	496
PLEKHA4	NXPE3	Q969Y0	472
PLEKHA4	TAC4	Q86UU9	435
PLEKHA4	RECQL4	O94761	433
PLEKHA4	EFTUD2	Q15029	427
PLEKHA4	RAVER1	Q8IY67	417
PLEKHA4	SLC6A20	Q9NP91	406
PLEKHA4	LZTFL1	Q9NQ48	401
PLEKHA4	HSPA1A	P08107	397
PLEKHA4	PLEKHA2	Q9HB19	394

IntAct

15 interactions, top by confidence:

A	B	Type	Score
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
ankX	PLEKHA4	psi-mi:“MI:0915”(physical association)	0.520
PLEKHA4	SHANK3	psi-mi:“MI:0915”(physical association)	0.370
ABL1	PLEKHA4	psi-mi:“MI:0915”(physical association)	0.370
PLEKHA4	PTPN11	psi-mi:“MI:0915”(physical association)	0.370
CCNG1	PLEKHA4	psi-mi:“MI:0915”(physical association)	0.370
PLEKHA4	PRKAA1	psi-mi:“MI:0915”(physical association)	0.370
BMI1	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
BMI1	MEIS3P1	psi-mi:“MI:0914”(association)	0.350
PLEKHA4	EEF1G	psi-mi:“MI:0915”(physical association)	0.000
PLEKHA4	KAT5	psi-mi:“MI:0915”(physical association)	0.000
PLEKHA4	RIF1	psi-mi:“MI:0915”(physical association)	0.000
PLEKHA4	SETDB1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (2977): PLEKHA4 (Two-hybrid), PLEKHA4 (Two-hybrid), EEF1G (Two-hybrid), KAT5 (Two-hybrid), LRIF1 (Two-hybrid), SETDB1 (Two-hybrid), PLEKHA4 (Two-hybrid), KLHL12 (Two-hybrid), MEI4 (Two-hybrid), KLHL12 (Affinity Capture-Western), KLHL12 (Co-localization), AAMP (Affinity Capture-MS), AARS (Affinity Capture-MS), ABCB7 (Affinity Capture-MS), ABCF1 (Affinity Capture-MS)

ESM2 similar proteins: A2A699, A4D1S0, A6NEL2, A8MVW0, B0BN44, B2RU40, C9JH25, D4A9R4, O43593, P03972, P0CG20, P0DPE3, P60669, P79295, Q14761, Q1HCM0, Q2M3G4, Q3UPH7, Q5F267, Q5FWE3, Q5SW24, Q5U2P6, Q5XJV6, Q64322, Q64697, Q6P1B3, Q6PE13, Q6UWD8, Q6ZS72, Q80W87, Q8BG26, Q8BZW2, Q8C310, Q8C708, Q8CII8, Q8IYJ0, Q8NAV2, Q8TER5, Q8VC98, Q8WZ75

Diamond homologs: B6RSP1, D3ZL52, G9CGD6, O08967, O43739, P54644, P60669, P97434, P97696, Q3UIL6, Q5DU31, Q6IQ23, Q6WCQ1, Q6ZNL6, Q7TQG1, Q80UZ0, Q80VL0, Q80YA9, Q86IV4, Q8BH49, Q8C4V1, Q8N264, Q8N4B1, Q8VC98, Q8WWN9, Q8WXI2, Q99KW3, Q9ERE6, Q9ERS5, Q9H4M7, Q9HAU0, Q9HB19, Q9Y2H5, Q9Z1T4, A2CEA7, A7KAN4, I1S8Q3, O14827, P0CN90, P0CN91

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

190 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	148
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2828 predictions. Top by Δscore:

Variant	Effect	Δscore
19:48838130:C:CC	acceptor_gain	1.0000
19:48841147:AC:A	donor_gain	1.0000
19:48841148:CC:C	donor_gain	1.0000
19:48845615:CT:C	acceptor_gain	1.0000
19:48845617:C:CC	acceptor_gain	1.0000
19:48845626:T:TC	acceptor_gain	1.0000
19:48847896:TTAC:T	donor_loss	1.0000
19:48847897:TACC:T	donor_loss	1.0000
19:48847898:ACC:A	donor_loss	1.0000
19:48847898:ACCT:A	donor_gain	1.0000
19:48847898:ACCTC:A	donor_gain	1.0000
19:48847899:C:CT	donor_loss	1.0000
19:48847899:CCTC:C	donor_gain	1.0000
19:48847899:CCTCC:C	donor_gain	1.0000
19:48847902:C:A	donor_gain	1.0000
19:48848036:CTGTC:C	acceptor_gain	1.0000
19:48848037:TGTC:T	acceptor_gain	1.0000
19:48848038:GTC:G	acceptor_gain	1.0000
19:48848039:TC:T	acceptor_gain	1.0000
19:48848040:CC:C	acceptor_gain	1.0000
19:48848041:C:CC	acceptor_gain	1.0000
19:48852329:CAGGT:C	acceptor_gain	1.0000
19:48852333:T:C	acceptor_gain	1.0000
19:48852333:T:TC	acceptor_gain	1.0000
19:48852336:C:CT	acceptor_gain	1.0000
19:48852337:A:AC	acceptor_gain	1.0000
19:48852337:A:C	acceptor_gain	1.0000
19:48853676:GCTCA:G	donor_loss	1.0000
19:48853677:CTCA:C	donor_loss	1.0000
19:48853678:TCACC:T	donor_loss	1.0000

AlphaMissense

4919 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:48861659:A:G	W76R	1.000
19:48861659:A:T	W76R	1.000
19:48865506:C:A	K63N	1.000
19:48865506:C:G	K63N	1.000
19:48860394:C:A	W144C	0.999
19:48860394:C:G	W144C	0.999
19:48860396:A:G	W144R	0.999
19:48860396:A:T	W144R	0.999
19:48861405:A:G	F121S	0.999
19:48861473:G:C	S98R	0.999
19:48861473:G:T	S98R	0.999
19:48861475:T:G	S98R	0.999
19:48861629:A:C	Y86D	0.999
19:48861630:A:C	F85L	0.999
19:48861630:A:T	F85L	0.999
19:48861632:A:G	F85L	0.999
19:48861652:A:T	V78D	0.999
19:48861654:G:C	F77L	0.999
19:48861654:G:T	F77L	0.999
19:48861655:A:G	F77S	0.999
19:48861656:A:G	F77L	0.999
19:48861657:C:A	W76C	0.999
19:48861657:C:G	W76C	0.999
19:48861662:G:T	R75S	0.999
19:48861667:T:A	K73I	0.999
19:48861669:C:A	W72C	0.999
19:48861669:C:G	W72C	0.999
19:48861671:A:G	W72R	0.999
19:48861671:A:T	W72R	0.999
19:48865508:T:C	K63E	0.999

dbSNP variants (sampled 300 via entrez): RS1000075488 (19:48855870 A>G,T), RS1000148653 (19:48856942 A>G), RS1000213220 (19:48846229 G>A), RS1000244107 (19:48845871 C>T), RS1000371263 (19:48866885 C>G), RS1000545623 (19:48844940 G>A,C), RS1000572694 (19:48850534 A>C), RS1000659805 (19:48870534 AG>A), RS1000755666 (19:48838285 A>C), RS1000983346 (19:48844729 T>A,C), RS1000993143 (19:48848485 C>A), RS1001102979 (19:48837840 G>A), RS1001191812 (19:48839140 C>T), RS1001264734 (19:48856038 G>A), RS1001329919 (19:48863448 G>T)

Disease associations

OMIM: gene MIM:607769 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST004611_154	High light scatter reticulocyte count	5.000000e-09
GCST004611_155	High light scatter reticulocyte count	6.000000e-13
GCST004612_176	High light scatter reticulocyte percentage of red cells	4.000000e-10
GCST004612_177	High light scatter reticulocyte percentage of red cells	1.000000e-14
GCST004619_64	Reticulocyte fraction of red cells	4.000000e-13
GCST004619_94	Reticulocyte fraction of red cells	3.000000e-15
GCST004622_79	Reticulocyte count	7.000000e-11
GCST004622_80	Reticulocyte count	1.000000e-12
GCST90002385_518	High light scatter reticulocyte count	4.000000e-33
GCST90002385_519	High light scatter reticulocyte count	2.000000e-34
GCST90002386_214	High light scatter reticulocyte percentage of red cells	5.000000e-38
GCST90002387_149	Immature fraction of reticulocytes	2.000000e-14
GCST90002387_150	Immature fraction of reticulocytes	5.000000e-19
GCST90002390_661	Mean corpuscular hemoglobin	2.000000e-10
GCST90002390_662	Mean corpuscular hemoglobin	3.000000e-14
GCST90002392_78	Mean corpuscular volume	6.000000e-10
GCST90002405_555	Reticulocyte count	8.000000e-31
GCST90002405_556	Reticulocyte count	4.000000e-29
GCST90002406_533	Reticulocyte fraction of red cells	2.000000e-36
GCST90002406_534	Reticulocyte fraction of red cells	2.000000e-34

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007986	reticulocyte count
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, increases abundance, increases expression	3
Benzo(a)pyrene	increases expression, increases methylation, affects methylation, decreases methylation	2
Nickel	increases expression	2
Cadmium Chloride	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
entinostat	increases expression	1
abrine	increases expression	1
eprenetapopt	affects expression, affects reaction	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	increases expression, increases abundance	1
Arsenic	affects expression, increases abundance	1
Cadmium	decreases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Camptothecin	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Lipopolysaccharides	increases expression, decreases reaction	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases expression	1
1-Methyl-4-phenylpyridinium	increases expression	1
Sodium Selenite	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1GZ	Abcam A-549 PLEKHA4 KO 1	Cancer cell line	Male
CVCL_B2PI	Abcam A-549 PLEKHA4 KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer